Literature DB >> 27230994

Symptomatic knee osteonecrosis in patients with systemic lupus erythematosus: a case-control study.

Lidan Zhao1, Xiuhua Wu1, Honghua Wu2, Jinmei Su1, Wen Zhang1, Yan Zhao1, Xuan Zhang1, Wenjie Zheng3.   

Abstract

To explore the associated risk factors of symptomatic knee osteonecrosis (KON) in patients with systemic lupus erythematosus (SLE), we conducted a retrospective case-control study to compare the clinical and laboratory features between SLE patients with and without symptomatic KON matched by age and gender. Univariate and multivariate regression analyses were used to evaluate possible associated risk factors. Twenty (one male, nineteen females) out of 3941 lupus patients were identified as symptomatic KON, which was confirmed by magnetic resonance imaging. The mean age at KON onset was 34.4 (range 12-67) years, and the median course of lupus at KON onset was 72.5 (range 8-123) months. Univariate and multivariate analyses identified that the prevalence of cutaneous vasculitis (OR 5.23; 95 % CI 1.11-24.70), hyperfibrinogenemia (OR 4.75; 95 % CI 1.08-20.85), and elevated IgG levels (OR 6.05; 95 % CI 1.58-23.16) were statistically higher in KON group, and hydroxychloroquine (HCQ) usage was statistically lower in KON group (OR 0.27; 95 % CI 0.07-0.97). Glucocorticoid usage, in terms of maximal dose, duration of treatment, and the percentage of receiving methylprednisolone pulse therapy, did not show statistical difference between the two groups (p > 0.05). Symptomatic KON is a relatively rare complication of SLE. Cutaneous vasculitis, hyperfibrinogenemia, and elevated IgG levels are possible risk factors, whereas HCQ may provide a protective effect. Our results suggest that lupus activity as well as hypercoagulation status may play a role in the pathogenesis of KON in lupus.

Entities:  

Keywords:  Knee; Osteonecrosis; Systemic lupus erythematosus (SLE)

Mesh:

Year:  2016        PMID: 27230994     DOI: 10.1007/s00296-016-3502-7

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  27 in total

1.  Risk factors for avascular necrosis of bone in patients with systemic lupus erythematosus: is there a role for antiphospholipid antibodies?

Authors:  M Y Mok; V T Farewell; D A Isenberg
Journal:  Ann Rheum Dis       Date:  2000-06       Impact factor: 19.103

2.  Incidence of osteonecrosis associated with corticosteroid therapy among different underlying diseases: prospective MRI study.

Authors:  Tomonori Shigemura; Junichi Nakamura; Shunji Kishida; Yoshitada Harada; Seiji Ohtori; Koya Kamikawa; Nobuyasu Ochiai; Kazuhisa Takahashi
Journal:  Rheumatology (Oxford)       Date:  2011-08-24       Impact factor: 7.580

Review 3.  Therapy Insight: osteoporosis and osteonecrosis in systemic lupus erythematosus.

Authors:  Nancy E Lane
Journal:  Nat Clin Pract Rheumatol       Date:  2006-10

4.  Risk factors for avascular bone necrosis in systemic lupus erythematosus.

Authors:  C C Mok; C S Lau; R W Wong
Journal:  Br J Rheumatol       Date:  1998-08

5.  Avascular necrosis of bone in systemic lupus erythematosus: possible role of haemostatic abnormalities.

Authors:  K Nagasawa; Y Ishii; T Mayumi; Y Tada; A Ueda; Y Yamauchi; T Kusaba; Y Niho
Journal:  Ann Rheum Dis       Date:  1989-08       Impact factor: 19.103

Review 6.  Hydroxychloroquine as an anti-thrombotic in antiphospholipid syndrome.

Authors:  Cristina Belizna
Journal:  Autoimmun Rev       Date:  2014-12-19       Impact factor: 9.754

7.  Osteonecrosis in systemic lupus erythematosus, steroid-induced or a lupus-dependent manifestation?

Authors:  A Rascu; K Manger; H G Kraetsch; J R Kalden; B Manger
Journal:  Lupus       Date:  1996-08       Impact factor: 2.911

8.  Avascular necrosis in systemic lupus erythematosus. Silent symmetric osteonecroses.

Authors:  J H Klippel; L H Gerber; L Pollak; J L Decker
Journal:  Am J Med       Date:  1979-07       Impact factor: 4.965

Review 9.  Osteonecrosis secondary to antiphospholipid syndrome: a case report, review of the literature, and treatment strategy.

Authors:  Waqar Haque; Huseyin Kadikoy; Omar Pacha; Joseph Maliakkal; Vu Hoang; Abdul Abdellatif
Journal:  Rheumatol Int       Date:  2009-12-12       Impact factor: 2.631

10.  Corticosteroid therapy associated with ischemic necrosis of bone in systemic lupus erythematosus.

Authors:  T M Zizic; C Marcoux; D S Hungerford; J V Dansereau; M B Stevens
Journal:  Am J Med       Date:  1985-11       Impact factor: 4.965

View more
  3 in total

1.  Systemic lupus erythematosus patients with high disease activity are associated with accelerated incidence of osteonecrosis: a systematic review and meta-analysis.

Authors:  Kui Zhang; Yan Zheng; Junfeng Jia; Jin Ding; Zhenbiao Wu
Journal:  Clin Rheumatol       Date:  2017-09-25       Impact factor: 2.980

Review 2.  Long-lasting severe knee pain in a SLE patient after renal transplantation: what is the reason? A case report and literature review.

Authors:  Anna Masiak; Iga Kościńska; Beata Rutkowska; Zbigniew Zdrojewski
Journal:  Rheumatol Int       Date:  2021-10-19       Impact factor: 2.631

3.  Anti-RNP Antibody: A Potential Novel Predictor for Osteonecrosis in Systemic Lupus Erythematosus.

Authors:  Jiangbiao Xiong; Gang Wang; Tian Xu; Ren Liu; Shujiao Yu; Yan Wang; Rui Wu
Journal:  Front Med (Lausanne)       Date:  2022-04-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.